Answers are grounded in this paper and cite their sources.
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that often requires long-term management. Probiotics have been investigated as adjunctive approaches for AD, but their effects are highly strain specific. Among these, Ligilactobacillus salivarius has shown potential in previous AD studies, yet the effects of different strains remain insufficiently characterized. In this study, we screened 19 human-derived L. salivarius isolates and selected Ls.0403, which exhibited favorable probiotic-related properties, for further evaluation. We compared oral live and heat-killed Ls.0403 in mice with MC903-induced AD-like skin inflammation. Both Live-Ls and HK-Ls alleviated AD-like skin inflammation, with HK-Ls showing greater improvements in several measured outcomes. Compared with Live-Ls-treated mice, HK-Ls-treated mice showed significantly lower serum CCL17/TARC levels and skin Tslp expression, together with significantly higher skin Lor expression. HK-Ls was also associated with changes in fecal bacterial community structure and cecal metabolic features, together with lower Enterobacteriaceae abundance and circulating lipopolysaccharide levels. Of the 1897 metabolic features altered by MC903 induction, 1705 (89.9%) showed shifts in the opposite direction in HK-Ls-treated mice relative to model mice. Antibiotic pretreatment markedly reduced the fecal bacterial 16S rRNA gene signal and attenuated HK-Ls-associated reductions in scratching frequency, skin mast-cell counts, and Tslp expression. These results show that Ls.0403 retains biological activity after heat inactivation in mice and support further evaluation of HK-Ls as an oral postbiotic for attenuating AD-like skin inflammation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: